Thursday’s insider activity: Major sells dominate trading By Investing.com
Investing.com reported U.S. insider trading for July 16, 2026. Major buys included Boundless Bio (63,969 shares, about $155.6k), ADIAL Pharmaceuticals (3,233 shares, $8,690), FIS (1,386 shares, $57.4k) and Cardiff Oncology (34,364 shares plus warrants). Major sells included Celcuity (3.1M shares, about $317.8M), Arista Networks (300k shares, about $54.2M), Butterfly Network (4.0M shares, about $29.4M), CoreWeave (307,692 shares, about $24.8M) and Venture Global (555,556 shares, about $14.3M).
How this was made
The 30-second read
Why it matters
The only actionable content is the disclosed transaction details (share counts, prices, and some 10b5-1 context). Without accompanying earnings, guidance, clinical, or deal catalysts, the trading edge is mainly short-term sentiment rather than fundamental repricing.
Market read
Traders may use the large sell sizes and the presence or absence of 10b5-1 context as a near-term sentiment input, but the article lacks new fundamental catalysts.
What to watch
The article does not provide whether these trades were preplanned relative to any new negative news, nor does it include subsequent guidance, trial results, or contract updates that would validate the signal.
Background
The article is a roundup of reported insider buying and selling activity for July 16, 2026, across multiple U.S. public companies.
Ticker impact
ADIAL Pharmaceuticals saw additional shareholder purchases totaling 3,233 shares at $2.65 and $2.75 on July 14 and July 16.
Low-to-moderate near-term support; follow-through depends on broader market/analyst updates.
The article frames the stock as down sharply and mentions analyst targets, but the only new fact here is the disclosed purchases.
Fidelity National Information Services’ independent chairman bought 1,386 shares at $41.39 via stock-for-cash retainer under a 10b5-1 plan.
Minimal incremental price impact expected.
The transaction is tied to compensation mechanics and a prearranged trading plan, reducing signal strength.
Cardiff Oncology CEO bought 34,364 shares at $1.455 and also acquired 34,364 warrants with $1.33 exercise price on July 14.
Potential short-term support, but likely limited without additional catalysts.
The disclosure is concrete and recent, yet the article lacks new fundamental drivers beyond the transaction details.
Ares Dynamic Credit Allocation Fund received a $4.0 million institutional purchase of 160,000 Series D preferred shares at $25.00.
Small positive read-through; unlikely to drive a major repricing alone.
The article does not state terms beyond price and amount, and it is a fund-level transaction rather than an operating catalyst.
Arista Networks shareholder Andreas Bechtolsheim sold 300,000 shares at about $176.18 to $185.00 under a 10b5-1 plan on July 14.
Limited incremental impact; any effect likely fades quickly.
The article explicitly attributes the sale to a preplanned 10b5-1 program, reducing informational content.
Butterfly Network director and 10% owner sold 4,013,452 shares over three days, totaling about $29.4 million, under a 10b5-1 plan.
Potential short-term pressure, especially if traders extrapolate from the sale size.
The transaction is substantial and recent, but 10b5-1 and estate-planning context can mute the signal.
CoreWeave CEO Michael Intrator sold 307,692 shares for about $24.8 million on July 14 under a 10b5-1 plan.
Mild-to-moderate near-term negative bias possible.
The disclosure is specific and time-linked to stock weakness, yet 10b5-1 reduces the inference of new negative information.
Venture Global’s general counsel exercised options for 555,556 shares at $0.79 and sold the same day at about $12.72 to $13.25.
Limited impact; likely no sustained trend from this alone.
The article describes a same-day exercise and sale with a large price spread, consistent with planned liquidity rather than a new fundamental thesis.
Market effects
No single sector catalyst; the piece is a cross-section of insider activity across biotech, software/IT, and funds.
Primarily U.S. micro-to-mid cap sentiment read-through, not a macro driver.
Limited, since the disclosures are company-specific and not tied to global policy or cross-border deals.
Counterpoint
Many cited sales are under Rule 10b5-1 or for estate planning/compensation mechanics, so the informational value for fundamentals may be overstated.
Key entities
- issuerBoundless Bio, Inc.
10% owner and affiliate bought 63,969 shares at about $2.43 to $2.44 over July 14-16.
- issuerCelcuity Inc.
Baker Bros. Advisors and related persons sold about 3.1 million shares at $102.50 for roughly $317.75 million.
- issuerCoreWeave, Inc.
CEO sold 307,692 shares for about $24.8 million on July 14 under a 10b5-1 plan.
